Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Big pharma Phase III setbacks

Two pharmaceutical companies, Roche and Pharmacia (PHA), announced that they halted development of compounds following unfavorable Phase III data. Roche said it has discontinued late-stage clinical development of two matrix metalloproteinase inhibitors (MMPIs) after interim

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers